Colorectal cancer

The Lancet

Volumn 383, Issue 9927, 2014, Pages 1490-1502

  Brenner, Hermann ^a   Kloor, Matthias ^b   Pox, Christian Peter ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; APC PROTEIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PROTEIN MSH2; REGORAFENIB;

ADJUVANT CHEMOTHERAPY; ALCOHOL CONSUMPTION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; COLONOSCOPY; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENE MUTATION; HELICOBACTER INFECTION; HEREDITARY COLORECTAL CANCER; HORMONE SUBSTITUTION; HUMAN; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASE; LIFESTYLE; MICROSATELLITE INSTABILITY; MOLECULAR PATHOLOGY; OBESITY; OCCULT BLOOD; OVERALL SURVIVAL; PRIMARY PREVENTION; PRIORITY JOURNAL; REHABILITATION; SECONDARY PREVENTION; SMOKING; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; MISMATCH REPAIR; MULTIMODALITY CANCER THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; PATIENT CARE TEAM; PRIMARY PREVENTION; PROGNOSIS; RISK FACTORS; SECONDARY PREVENTION; SEX FACTORS; SURVIVAL RATE; TERTIARY PREVENTION; WORLD HEALTH;

EID: 84899628178     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61649-9     Document Type: Conference Paper

References (138)

1. Ferlay J, Shin HR, Bray F, Forman D., Mathers C, Parkin DM GLOBOCAN 2008-cancer incidence and mortality worldwide: IARC CancerBase No 10. Lyon: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr (accessed April 19, 2013).
2. Siegel R, DeSantis C, Virgo K., et al Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
3. Center MM, Jemal A, Smith R.A., Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-78.
4. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
5. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-94.
6. Stock C, Pulte D, Haug U., Brenner H. Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointest Endosc 2012; 75: 621-30.
7. Bosetti C, Levi F, Rosato V., et al Recent trends in colorectal cancer mortality in Europe. Int J Cancer 2011; 129: 180-91.
8. Guo P, Huang ZL, Yu P, Li K. Trends in cancer mortality in China: an update. Ann Oncol 2012; 23: 2755-62.
9. World Health Organization mortality database. http://www.who.int/whosis/ mort/download/en/index.html (accessed Oct 7, 2012).
10. Brenner H, Bouvier AM, Foschi R, et a.l., and the EUROCARE Working Group. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer 2012; 131: 1649-58.
11. Sankaranarayanan R, Swaminathan R, Brenner H., et al Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010; 11: 165-73.
12. Taylor DP, Burt RW, Williams M.S., Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology 2010; 138: 877-85.
13. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-45.
14. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer 2009; 124: 2406-15.
15. Fedirko V, Tramacere I, Bagnardi V., et al Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol 2011; 22: 1958-72.
16. Chan DS, Lau R, Aune D., et al Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS One 2011; 6: e20456.
17. Ma Y, Yang Y, Wang F., et al Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One 2013; 8: e53916.
18. Jiang Y, Ben Q, Shen H., Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2011; 26: 863-76.
19. Sonnenberg A, Genta RM Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 2013; 108: 208-15.
20. Kostic AD, Gevers D, Pedamallu C.S., et al Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292-98.
21. Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 2011; 53: 870-78.
22. Boyle T, Keegel T, Bull F., Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 1548-61.
23. Lin KJ, Cheung WY, Lai J.Y., Giovannucci EL The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 2012; 130: 419-30.
24. Bosetti C, Rosato V, Gallus S., Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
25. Rothwell PM, Fowkes FG, Belch J.F., Ogawa H., Warlow CP, Meade TW Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
26. Brenner H, Chang-Claude J, Seiler C.M., Rickert A., Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154: 22-30.
27. Elmunzer BJ, Hayward RA, Schoenfeld P.S., Saini SD, Deshpande A, Waljee AK Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2012; 9: e1001352.
28. Aune D, Lau R, Chan D.S., et al Nonlinear reduction in risk for colorectal cancer by fruit and vegetable intake based on meta-analysis of prospective studies. Gastroenterology 2011; 141: 106-18.
29. Aune D, Chan DS, Lau R, et al Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 2011; 343: d6617.
30. Aune D, Lau R, Chan D.S., et al Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. Ann Oncol 2012; 23: 37-45.
31. Wu S, Feng B, Li K., et al Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. Am J Med 2012; 125: 551-59.
32. Lochhead P, Chan AT Statins and colorectal cancer. Clin Gastroenterol Hepatol 2013; 11: 109-18.
33. Ma Y, Zhang P, Wang F., Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011; 29: 3775-82.
34. Lichtenstein P, Holm NV, Verkasalo P.K., et al Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
35. Burn J, Mathers J, Bishop D T. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res 2013; 191: 157-83.
36. Theodoratou E, Montazeri Z, Hawken S., et al Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 2012; 104: 1433-57.
37. Dunlop MG, Tenesa A, Farrington S.M., et al Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Gut 2013; 62: 871-81.
38. Hutter CM, Chang-Claude J, Slattery M.L., et al Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res 2012; 72: 2036-44.
39. Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours, 7th edn. New York: Wiley-Blackwell, 2009.
40. Sadanandam A, Lyssiotis CA, Homicsko K, et al A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-25.
41. De Sousa E Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-18.
42. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
43. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-30.
44. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
45. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-27.
46. Bettington M, Walker N, Clouston A., Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62: 367-86.
47. Herman JG, Umar A, Polyak K., et al Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-75.
48. Parsons MT, Buchanan DD, Thompson B, Young J.P., Spurdle AB Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012; 49: 151-57.
49. Jasperson KW, Tuohy TM, Neklason D.W., Burt RW Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-58.
50. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-32.
51. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993; 90: 10914-21.
52. Roy HK, Lynch HT Diagnosing Lynch syndrome: is the answer in the mouth? Gut 2003; 52: 1665-67.
53. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87, e3.
54. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25: 7531-37.
55. Jung SB, Lee HI, Oh H.K., Shin IH, Jeon CH Clinico-pathologic parameters for prediction of microsatellite instability in colorectal cancer. Cancer Res Treat 2012; 44: 179-86.
56. Shia J, Ellis NA, Paty P.B., et al Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003; 27: 1407-17.
57. Lindor NM, Burgart LJ, Leontovich O, et al Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 1043-48.
58. Kloor M, Huth C, Voigt A.Y., et al Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncol 2012; 13: 598-606.
59. Popat S, Hubner R, Houlston RS Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.
60. Fallik D, Borrini F, Boige V., et al Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63: 5738-44.
61. Bertagnolli MM, Niedzwiecki D, Compton C.C., et al Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-21.
62. Dolcetti R, Viel A, Doglioni C., et al High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805-13.
63. Schwitalle Y, Kloor M, Eiermann S., et al Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134: 988-97.
64. Galon J, Costes A, Sanchez-Cabo F, et al Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-64.
65. Galon J, Pagès F, Marincola F.M., et al Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.
66. Amado RG, Wolf M, Peeters M., et al Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
67. Di Nicolantonio F., Martini M, Molinari F., et al Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12.
68. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer-an example of personalised medicine in action. Cancer Treat Rev 2013; 39: 592-601.
69. Arnaud JP, Bergamaschi R, Schloegel M. Synchronous carcinoma of the colon and rectum: prognostic and therapeutic implications. Am J Surg 1989; 157: 299-302.
70. Park SH, Lee JH, Lee S.S., et al CT colonography for detection and characterisation of synchronous proximal colonic lesions in patients with stenosing colorectal cancer. Gut 2012; 61: 1716-22.
71. Puli SR, Bechtold ML, Reddy J.B., Choudhary A., Antillon MR, Brugge WR How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann Surg Oncol 2009; 16: 254-65.
72. Puli SR, Bechtold ML, Reddy J.B., Choudhary A., Antillon MR Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. Dig Dis Sci 2010; 55: 1221-29.
73. Al-Sukhni E., Milot L, Fruitman M., et al Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 2212-23.
74. Kaur H, Choi H, You Y.N., et al MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics 2012; 32: 389-409.
75. Evans J, Patel U, Brown G. Rectal cancer: primary staging and assessment after chemoradiotherapy. Semin Radiat Oncol 2011; 21: 169-77.
76. Leufkens AM, van den Bosch MA, van Leeuwen MS, Siersema PD. Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review. Scand J Gastroenterol 2011; 46: 887-94.
77. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674-84.
78. Floriani I, Torri V, Rulli E., et al Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31: 19-31.
79. Sietses C, Meijerink MR, Meijer S, van den Tol MP. The impact of intraoperative ultrasonography on the surgical treatment of patients with colorectal liver metastases. Surg Endosc 2010; 24: 1917-22.
80. Rafaelsen SR, Jakobsen A. Contrast-enhanced ultrasound vs multidetector-computed tomography for detecting liver metastases in colorectal cancer: a prospective, blinded, patient-by-patient analysis. Colorectal Dis 2011; 13: 420-25.
81. Mitry E, Guiu B, Cosconea S., Jooste V, Faivre J, Bouvier AM Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010; 59: 1383-88.
82. Choi DJ, Kwak JM, Kim J, Woo S.U., Kim SH Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer: its role in staging and impact on treatment strategy. J Surg Oncol 2010; 102: 588-92.
83. Kirke R, Rajesh A, Verma R., Bankart MJ Rectal cancer: incidence of pulmonary metastases on thoracic CT and correlation with T staging. J Comput Assist Tomogr 2007; 31: 569-71.
84. Tan KK, Lopes GL Jr, Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. J Gastrointest Surg 2009; 13: 642-48.
85. Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18) F-FDG PET: a randomized study. J Nucl Med 2009; 50: 1036-41.
86. Burton S, Brown G, Daniels I.R., Norman AR, Mason B, Cunningham D, and the Royal Marsden Hospital, Colorectal Cancer Network. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer 2006; 94: 351-57.
87. MacDermid E, Hooton G, MacDonald M., et al Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis 2009; 11: 291-95.
88. Segelman J, Singnomklao T, Hellborg H., Martling A. Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Dis 2009; 11: 768-74.
89. Wille-Jørgensen P, Sparre P, Glenthøj A, et al. Result of the implementation of multidisciplinary teams in rectal cancer. Colorectal Dis 2013; 15: 410-13.
90. Heald RJ, Ryall RD Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-82.
91. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26: 303-12.
92. Caricato M, Borzomati D, Ausania F., Valeri S, Rosignoli A, Coppola R. Prognostic factors after surgery for locally recurrent rectal cancer: an overview. Eur J Surg Oncol 2006; 32: 126-32.
93. West NP, Hohenberger W, Weber K., Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010; 28: 272-78.
94. Kuhry E, Schwenk WF, Gaupset R, Romild U., Bonjer HJ Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008; 2: CD003432.
95. Liang Y, Li G, Chen P., Yu J. Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence. Eur J Surg Oncol 2008; 34: 1217-24.
96. Trastulli S, Cirocchi R, Listorti C., et al Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. Colorectal Dis 2012; 14: e277-96.
97. Trastulli S, Farinella E, Cirocchi R., et al Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. Colorectal Dis 2012; 14: e134-56.
98. van Gijn W., Marijnen CA, Nagtegaal I.D., et al, and the Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-82.
99. Aschele C, Cionini L, Lonardi S., et al Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-80.
100. Hofheinz RD, Wenz F, Post S., et al Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579-88.
101. Frasson M, Garcia-Granero E, Roda D., et al Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer 2011; 117: 3118-25.
102. Sauer R, Liersch T, Merkel S., et al Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33.
103. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W., Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-23.
104. Ngan S.Y., Burmeister B, Fisher R.J., et al Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30: 3827-33.
105. Rödel C., Trojan J, Bechstein W.O., Woeste G. Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? Dig Dis 2012; 30 (suppl 2): 102-08.
106. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13: 1152-60.
107. Gill S, Loprinzi CL, Sargent D.J., et al Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-806.
108. Twelves C, Scheithauer W, McKendrick J., et al Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012; 23: 1190-97.
109. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-16.
110. Haller DG, Tabernero J, Maroun J., et al Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-71.
111. Yothers G, O'Connell MJ, Allegra CJ, et al Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-74.
112. de Gramont A., Van Cutsem E, Schmoll HJ, et al Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-33.
113. Alberts SR, Sargent DJ, Nair S, et al Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383-93.
114. Van Cutsem E., Labianca R, Bodoky G., et al Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-25.
115. Papadimitriou CA, Papakostas P, Karina M., et al A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med 2011; 9: 10.
116. Gray R, Barnwell J, McConkey C., Hills RK, Williams NS, Kerr DJ, and the Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-29.
117. Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 2010; 59: 838-58.
118. de Jong M.C., Pulitano C, Ribero D., et al Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250: 440-48.
119. Hewitson P, Glasziou P, Watson E., Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-49.
120. Brenner H, Stock C, Hoffmeister M. In the era of widespread endoscopy use randomized trials may strongly underestimate effects of colorectal cancer screening. J Clin Epidemiol 2013; 66: 1144-50.
121. Schoen RE, Pinsky PF, Weissfeld J.L., et al, and the PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345-57.
122. Zauber AG, Winawer SJ, O'Brien MJ, et al Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687-96.
123. Kaminski MF, Bretthauer M, Zauber A.G., et al The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 2012; 44: 695-702.
124. Duffy MJ, van Rossum LGM, van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011; 128: 03-11.
125. Brenner H, Tao S. Superior diagnostic performance of fecal immunochemical tests for hemoglobin in a head-to-head comparison with guaiac based fecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013; 49: 3049-54.
126. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med 2012; 55: 87-92.
127. Lansdorp-Vogelaar I., Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011; 33: 88-100.
128. Lange CPE, Campan M, Hinoue T., et al Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One 2012; 7: e50266.
129. de Wit M., Fijneman RJ, Verheul H.M., Meijer GA, Jimenez CR Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem 2013; 46: 466-79.
130. Ahlquist DA, Zou H, Domanico M., et al Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142: 248-56.
131. Knudsen AB, Lansdorp-Vogelaar I, Rutter C.M., et al Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010; 102: 1238-52.
132. Qaseem A, Denberg TD, Hopkins RH Jr, et al, and the Clinical Guidelines Committee of the American College of Physicians. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012; 156: 378-86.
133. von Karsa L., Patnick J, Segnan N., et al, and the European Colorectal Cancer Screening Guidelines Working Group. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013; 45: 51-59.
134. Levin TR, Jamieson L, Burley D.A., Reyes J., Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev 2011; 33: 101-10.
135. Mishra SI, Scherer RW, Geigle P.M., et al Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 2012; 8: CD007566.
136. Phipps AI, Baron J, Newcomb PA Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. Cancer 2011; 117: 4948-57.
137. Zell JA, Ziogas A, Bernstein L., et al Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study. Cancer Prev Res (Phila) 2010; 3: 865-75.
138. Liao X, Lochhead P, Nishihara R., et al Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-606.